Pentixapharm Holding AG (XTER:PTP) Short-Term Debt: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:PTP Pentixapharm Holding AG XTER:PTP
22 GF Score
Price €1.94
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Short-Term Debt?

Pentixapharm Holding AG XTER:PTP -2.02% 22 Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates XTER:PTP with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Pentixapharm Holding AG's Short-Term Debt for the quarter that ended in Mar. 2026 was €0.00 Mil.

Pentixapharm Holding AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Pentixapharm Holding AG Short-Term Debt Related Terms

Pentixapharm Holding AG Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG Short-Term Debt Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 0.00 0.00 0.00

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTER:PTP
22GF Score
Pentixapharm Holding AG XTER:PTP
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Pentixapharm Holding AG (XTER:PTP) has a Short-Term Debt of €0.00 Mil as of Mar. 2026.
Is Pentixapharm Holding AG's Short-Term Debt too high?
Pentixapharm Holding AG's current Short-Term Debt is €0.00 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Short-Term Debt compare to VRTX and REGN?
Pentixapharm Holding AG's Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Pentixapharm Holding AG's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current Short-Term Debt of €0.00 Mil. The current Short-Term Debt is €0.00 Mil. Pentixapharm Holding AG's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
22GF Score

Get the complete analysis for XTER:PTP

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.94
Price